Compare BLBD & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLBD | NRIX |
|---|---|---|
| Founded | 1927 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2013 | 2020 |
| Metric | BLBD | NRIX |
|---|---|---|
| Price | $57.79 | $15.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | ★ $67.20 | $29.46 |
| AVG Volume (30 Days) | 495.0K | ★ 716.8K |
| Earning Date | 05-11-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.78 | N/A |
| EPS | ★ 0.94 | N/A |
| Revenue | ★ $1,480,099,000.00 | $76,987,000.00 |
| Revenue This Year | $4.25 | N/A |
| Revenue Next Year | $4.21 | $29.30 |
| P/E Ratio | $61.82 | ★ N/A |
| Revenue Growth | 9.87 | ★ 99.31 |
| 52 Week Low | $30.15 | $8.18 |
| 52 Week High | $62.90 | $22.50 |
| Indicator | BLBD | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 53.02 | 43.33 |
| Support Level | $53.58 | $15.22 |
| Resistance Level | $58.57 | $16.49 |
| Average True Range (ATR) | 2.53 | 0.74 |
| MACD | -0.32 | 0.07 |
| Stochastic Oscillator | 28.48 | 40.49 |
Blue Bird Corp is an American bus manufacturing company. It is an independent designer and manufacturer of school buses. The company operates in two segments; the Bus segment which involves the design, engineering, manufacture, and sales of school buses and extended warranties; and the Parts segment which includes the sales of replacement bus parts. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada and Rest of the world.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.